A Phase 2 Extension Study To Enroll Subjects Who Were Enrolled In B5301001 Study

A Long-term Efficacy Assessment Following Initial Scar Revision Surgery And Phase 2 Open-label Study To Evaluate Safety Of Re-treatment With Pf-06473871

Study is a multicenter, two-part, open-label phase II study in adults, evaluating the safety and long-term efficacy of PF-06473871 one year after surgical revision and treatment with PF-06473871.

Inclusion Criteria:

• Subjects previously randomized to Pfizer clinical study B5301001.
• Subjects must be able to tolerate up to a 3 hour scar revision surgery under sedation and local anesthesia.

Exclusion Criteria:

• Pregnant female subject; breastfeeding female subjects; male subjects with partners currently pregnant.
• Any previous history of intolerable adverse reactions to PF-06473871, such as serious adverse events attributed to study drug or having been withdrawn due to AE in prerequisite study B5301001.